Obesity

Georgia

110 Obesity Trials near Georgia

Power is an online platform that helps thousands of Obesity patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Watermelon for Obesity

Tallahassee, Florida
The goal of this clinical trial is to evaluate the effect of daily fresh watermelon consumption for 6-weeks on gut health, including microbiome diversity, gut barrier and immune function in young adults with overweight and obesity. The main questions it aims to answer are: 1. Will consuming fresh watermelon daily for 6-weeks will improve intestinal barrier health and increase microbiome diversity such as an increased population of beneficial 'probiotic' bacteria when compared to control participants consuming a low-fat snack? 2. Will consuming fresh watermelon daily for six-weeks will improve other health measures, including body-composition, blood pressure, blood vessel function, blood lipid profiles, and measures of inflammation, as compared to control participants consuming a low-fat snack for the same time period?
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 30

36 Participants Needed

The purpose of this study is to assess obese patients with knee arthritis and determine the non-inferiority of a low dose steroid treatment vs. standard dose steroid treatment for two knee outcome measures: pain and function.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:55 - 85

40 Participants Needed

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity. The study will last up to 12 months.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4

200 Participants Needed

NNC0519-0130 for Obesity

Jacksonville, Florida
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

355 Participants Needed

Circadian rhythm disruption caused by shift work alters metabolic and hormonal pathways, which accelerates chronic disease onset, leading to decreased quality and quantity of life. Preclinical studies indicate that optimizing nutrient and sleep/rest timing can mitigate these effects. Female nightshift healthcare workers will be recruited to participate in a randomized crossover trial in which participants will be expected to follow the prescribed lifestyle intervention for eight weeks during the first or second eight-week periods of the study.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 50
Sex:Female

13 Participants Needed

Retatrutide for Obesity

Atlanta, Georgia
The purpose of this study is to evaluate the efficacy and safety of retatrutide in participants who have obesity or overweight (J1I-MC-GZBJ master protocol) including subsets of participants who have knee osteoarthritis (OA) (J1I-MC-GOA1) or who have obstructive sleep apnea (OSA) (J1I-MC-GSA1). This study will last about 89 weeks and will include up to 24 visits. Addendum (2) is optional and available to approximately 500 participants to continue treatment with retatrutide for up to an additional 24 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

2300 Participants Needed

The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:10 - 18

15 Participants Needed

The primary purpose of this study is to assess changes in epigenetic markers of aging and physiological parameters in overweight older adults consuming a mixed greens-based supplement over a 30-day period in a randomized crossover design.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:50 - 65

20 Participants Needed

This study is open to adults who are at least 18 years old and have * presumed or confirmed NASH together with overweight or obesity and * a body mass index (BMI) of 30 kg/m² or more, or * a BMI of 27 kg/m² and at least one weight-related health problem. People with a history of other chronic liver diseases cannot take part in this study. The purpose of this study is to find out whether a medicine called survodutide helps people living with obesity or overweight and a confirmed or presumed liver disease called nonalcoholic steatohepatitis (NASH) to have less liver fat and to lose weight. Participants are put into 2 groups randomly, which means by chance. 1 group gets different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants and doctors do not know who is in which group. Participants inject survodutide or placebo under their skin once a week for about 1 year. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly. Participants are in the study for about 1 year and 3 months. During this time, it is planned that participants visit the study site up to 14 times and receive 3 phone calls by the site staff. The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. At 3 of the visits, the participants' liver is measured using different imaging methods. The results are compared between the groups to see whether the treatment works.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

248 Participants Needed

Retatrutide for Obesity

Marietta, Georgia
This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

643 Participants Needed

LY3549492 for Obesity

Fleming Island, Florida
The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

275 Participants Needed

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136 for chronic weight management alone or in combination with Tirzepatide across a wide dose range in participants with Type 2 Diabetes. Participation in the study will last about 64 weeks.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

350 Participants Needed

LY3841136 for Obesity

Fleming Island, Florida
This trial is testing a new medication called LY3841136 to help adults who are overweight or obese manage their weight. The study aims to see if this medication is safe and effective over several months.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

263 Participants Needed

This trial is testing a new medicine called CagriSema to see if it can reduce kidney damage in people with chronic kidney disease, type 2 diabetes, and who are overweight or obese. The study will compare CagriSema to two other medicines.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

618 Participants Needed

LY3305677 for Obesity

Fleming Island, Florida
This trial is testing a new medication called LY3305677 to help adults who are obese or overweight manage their weight. The study will last over a year. Researchers want to see if this medication helps people lose weight and if it is safe to use.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2

179 Participants Needed

This trial is testing a new non-surgical weight loss method called GMA for obese people. It uses a tube with a camera to treat the stomach lining with argon gas and waterjet, which helps reduce hunger hormones.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:22 - 60

15 Participants Needed

LY3305677 for Obesity

Fleming Island, Florida
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2

1217 Participants Needed

The main purpose of this study is to show whether in these individuals, treatment with both mirikizumab and tirzepatide, compared with treatment with mirikizumab and placebo, leads to decrease or disappearance of UC symptoms, and loss of at least one-tenth of the overall body weight. Participation in this study will last up to 61 weeks, including 52 weeks of treatment.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

350 Participants Needed

This trial is testing a medication called retatrutide in people who have both obesity and heart disease. The study will last over two years to see if the medication is safe and effective.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3

1800 Participants Needed

The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

290 Participants Needed

Why Other Patients Applied

"I have a heart condition, and my fat is all in my chest, surrounding my heart. It's hard for me to exercise because my legs are thin and the upper body weight is too much — putting strain on my leg joints. It’s a vicious cycle. I am also post-menopausal, which adds additional weight loss difficulty. I also have stress with being a full time caregiver for my mom. I'm interested in trying a clinical trial."

DK
Obesity PatientAge: 56

"I need to lose weight because it's affecting my knees. I've already had a knee replacement and the second one is happening on the left knee in a few months. I've participated in a study in the past for a skin-related issue, and had a good experience. That's why I'm interested in joining a study for wieght loss."

KI
Obesity PatientAge: 69

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"I am applying for my daughter. She turns 12 this year and is overweight. She's 5'4" and 176 pounds. Would be great to enroll her in a clinical trial to see if this form of care could work for her. Realize that there's no guarantee, but I support her and we'd like to give it a try."

MW
Parent of PatientAge: 46

"I have tried to lose weight, but as I get older, it becomes harder and harder. I have lost weight in the past through diet and exercise, but it has been more difficult to accomplish as I age."

JP
Obesity PatientAge: 44

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials

Frequently Asked Questions

How much do Obesity clinical trials in Georgia pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do Obesity clinical trials in Georgia work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Obesity trials in Georgia 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Georgia for Obesity is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Georgia several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a Obesity medical study in Georgia?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest Obesity clinical trials in Georgia?

Most recently, we added Cagrilintide + CagriSema for Childhood Obesity, Cottonseed Oil for High Cholesterol and Low-calorie Diet for Impaired Fasting Glucose to the Power online platform.

What is the new treatment for obesity?

The “new” treatments are weekly injections of GLP-1–based drugs such as semaglutide (Wegovy) and the dual GIP/GLP-1 drug tirzepatide (Zepbound), which curb appetite and slow stomach emptying; in large trials they helped adults lose roughly 15-22 % of their starting weight over 12–18 months when combined with diet and exercise. They are prescription-only, must be used long-term to keep the weight off, and while most side-effects are mild stomach upset, they can be expensive and require close medical follow-up—so you and your clinician should weigh these pros and cons against other options like older pills, bariatric surgery, and structured lifestyle programs.

How much do I get paid for a clinical trial?

There is no single rate, but in the U.S. healthy-volunteer Phase I studies usually pay about $75–$150 for a short outpatient visit or $300–$500 per overnight, adding up to roughly $1,500–$6,000 for a multi-day study; later-phase trials for people who already have the illness typically offer a smaller stipend—often $25–$100 per visit—plus travel reimbursement. Amounts are set case-by-case by the study sponsor and ethics board, based on the time you give up, the inconvenience or discomfort involved (blood draws, overnight stays, special diets), and any out-of-pocket costs, and they must be prorated so you can stop at any time and still receive payment for the visits you’ve completed.

How much weight can you lose with ESG surgery?

Large studies find that people lose roughly 15–20 % of their starting weight after endoscopic sleeve gastroplasty—about 30–50 lb if you begin at 200–250 lb—and most keep the bulk of that off for at least two years when they stay in a structured nutrition and activity program. Your exact result can be higher or lower depending on your initial BMI, how closely you follow the dietary and lifestyle plan, and whether you attend regular follow-up visits with the bariatric team.

What weight is considered obese?

For adults, obesity starts at a body-mass index (BMI) of 30 kg/m²—so take your height in metres, square it, and multiply by 30 to see the weight cut-off. Example: 5′4″ (1.63 m) → 1.63² × 30 ≈ 88 kg / 194 lb; 6′0″ (1.83 m) → 1.83² × 30 ≈ 102 kg / 225 lb. BMI is only a quick gauge—muscle mass, ethnicity, waist size, and other health factors matter too—so use it as a starting point and confirm risks with your healthcare professional.

Who is eligible for tirzepatide?

Tirzepatide is eligible for adults in two settings: (1) as Mounjaro to improve blood-sugar control in type-2 diabetes, and (2) as Zepbound for weight management if you have obesity (BMI ≥ 30) or are overweight (BMI ≥ 27) with at least one related condition such as high blood pressure, abnormal cholesterol, sleep apnea, heart disease, or type-2 diabetes. You are NOT a candidate if you’re pregnant, under 18, or have a personal or family history of medullary thyroid cancer or MEN-2; your doctor will also screen for issues like pancreatitis, severe stomach problems, or other risks before prescribing. In short, meeting the diabetes or weight criteria and having no major contraindications makes you a potential candidate, but final approval comes after a thorough medical review.

What tests are done for unexplained weight gain?

Doctors usually start with a history and physical exam, then order a small “baseline” panel—complete blood count, comprehensive metabolic panel (kidney + liver), fasting glucose/HbA1c, cholesterol, thyroid-stimulating hormone, and a pregnancy test in women of child-bearing age. If exam findings point to a specific cause, they add focused tests: e.g., cortisol or prolactin for suspected hormone tumors, sex-hormone and ultrasound for possible PCOS, heart or kidney studies for fluid retention, or imaging of the pituitary/adrenal glands. In short, everyone gets the core labs, and any further blood work or scans are chosen only when your symptoms or medications suggest a particular problem.

Can a morbidly obese person lose weight without surgery?

Yes. Rigorous studies show that people with class III (“morbid”) obesity can shed 6-8 % of their starting weight through weekly lifestyle-coaching programs, and often 15-20 % when the same program is paired with new once-a-week injections such as semaglutide (Wegovy) or tirzepatide (Zepbound); endoscopic sleeve procedures add another non-surgical option in the same range. Because even a 5-10 % loss markedly improves blood pressure, diabetes and sleep-apnea, doctors usually start with dietitian-guided eating plans, gradual activity and behaviour counselling, then add medication if weight hasn’t dropped by about 5 % after three months—saving surgery for those who still need more help.

How to get rid of fat deposits on legs?

You can’t melt fat from your legs alone, so aim for gradual overall weight loss (a modest calorie deficit built around whole foods) while doing both full-body cardio and leg-strength exercises such as squats or lunges 2-3 times a week—the combo burns calories and builds muscle that makes legs look firmer as fat comes off. If your legs stay disproportionately large, painful or bruise easily, ask a clinician about lipedema or other medical causes, because lifestyle changes help most people but specialised treatment is sometimes needed.

How to get Ozempic for weight loss?

Ozempic (semaglutide) can be prescribed for weight loss, but it is technically an off-label use; most clinicians instead start with the weight-loss version of the same drug, Wegovy. To pursue either one, confirm you meet typical criteria (BMI ≥30, or ≥27 with a weight-related condition), then see a primary-care doctor, endocrinologist, or an obesity-medicine/telehealth service that can review your labs, rule out contraindications, and submit any required prior-authorization to your insurer or the manufacturer’s savings program. Expect a gradual dose-escalation schedule, routine follow-ups for side-effects such as nausea, and the need to pair the medication with diet and activity changes to maintain the ~15 % average weight loss seen in clinical trials.

Which drink is good for belly fat loss?

No drink can “melt” belly fat on its own; losing abdominal fat still comes down to taking in fewer calories than you burn. The most studied helpers are plain water (pre-meal water can curb appetite), unsweetened green tea or black coffee (their caffeine and, for green tea, catechins give a small metabolic boost). Choose these without added sugar, pair them with balanced meals and regular exercise, and they can support—rather than drive—belly-fat loss.

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security